Agenus to Participate in the Raymond James 2021 Human Health Innovation Conference
Agenus, a clinical-stage immuno-oncology company, will have its President and COO, Jennifer Buell, PhD, present at the Raymond James 2021 Human Health Innovation Conference on June 22, 2021, from 8:40 a.m. to 9:10 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Agenus, a clinical-stage immuno-oncology company, will have its President and COO, Jennifer Buell, PhD, present at the Raymond James 2021 Human Health Innovation Conference on June 22, 2021, from 8:40 a.m. to 9:10 a.m. ET. The presentation will focus on the company's extensive pipeline, which includes checkpoint antibodies, cell therapies, and vaccines to activate immune responses against cancer and infections. The session will be available via a live webcast on their website.
Details
News Market Reaction – AGEN
The recorded move for AGEN in the trading session of this news was +0.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennifer Buell, PhD, President and COO of Agenus, will present at the Raymond James 2021 Human Health Innovation Conference on Tuesday, June 22, 2021 from 8:40 a.m. to 9:10 a.m. ET.
The presentation will be webcast live and may be accessed on the company's website at https://investor.agenusbio.com/events-and-presentations.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.
Contact
Agenus Investor Relations
Jan Medina, CFA
Agenus
781-674-4490
Jan.Medina@agenusbio.com
Agenus Media Relations
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.